Immunovant (IMVT) Net Income Growth (5y) (2023 - 2026)

Immunovant (IMVT) Net Income Growth (5y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Immunovant 8.63 Bn 7.83 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2026 -38.13%
Mar 31, 2026 -39.33%
Dec 31, 2025 -28.34%
Sep 30, 2025 -43.50%
Jun 30, 2025 -35.19%
Mar 31, 2025 -38.95%
Dec 31, 2024 -57.97%
Sep 30, 2024 -49.41%
Jun 30, 2024 -34.09%
Mar 31, 2024 -52.84%
Dec 31, 2023 -42.18%